CDTX vs. GNTA, AVRO, LENZ, IKNA, TSBX, ALGS, TARA, ENTX, ATRA, and INAB
Should you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Genenta Science (GNTA), AVROBIO (AVRO), LENZ Therapeutics (LENZ), Ikena Oncology (IKNA), Turnstone Biologics (TSBX), Aligos Therapeutics (ALGS), Protara Therapeutics (TARA), Entera Bio (ENTX), Atara Biotherapeutics (ATRA), and IN8bio (INAB). These companies are all part of the "biological products, except diagnostic" industry.
Genenta Science (NASDAQ:GNTA) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
In the previous week, Cidara Therapeutics had 8 more articles in the media than Genenta Science. MarketBeat recorded 10 mentions for Cidara Therapeutics and 2 mentions for Genenta Science. Cidara Therapeutics' average media sentiment score of 0.17 beat Genenta Science's score of 0.12 indicating that Genenta Science is being referred to more favorably in the media.
Genenta Science has a net margin of 0.00% compared to Genenta Science's net margin of -73.46%. Cidara Therapeutics' return on equity of 0.00% beat Genenta Science's return on equity.
Genenta Science has higher earnings, but lower revenue than Cidara Therapeutics.
Cidara Therapeutics received 433 more outperform votes than Genenta Science when rated by MarketBeat users. However, 85.71% of users gave Genenta Science an outperform vote while only 70.24% of users gave Cidara Therapeutics an outperform vote.
Genenta Science currently has a consensus price target of $25.00, indicating a potential upside of 657.58%. Cidara Therapeutics has a consensus price target of $71.25, indicating a potential upside of 535.59%. Given Cidara Therapeutics' higher possible upside, analysts plainly believe Genenta Science is more favorable than Cidara Therapeutics.
Genenta Science has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.
15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 7.4% of Cidara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Genenta Science and Cidara Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Cidara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cidara Therapeutics Competitors List
Related Companies and Tools
